Company AbCellera Biologics Inc.

Equities

ABCL

CA00288U1066

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 26/04/2024 BST 5-day change 1st Jan Change
3.76 USD +3.58% Intraday chart for AbCellera Biologics Inc. -2.84% -34.15%

Business Summary

AbCellera Biologics Inc. is focused on the development of antibody-based drugs and is committed to improving discovery and development. It is engaged in antibody discovery and development engine is specifically designed to break the barriers of conventional discovery. It provides biotech and pharmaceutical companies with an advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. The Company uses the engine to both work with partners to build a large and diversified portfolio of royalty stakes in antibody drugs and to develop its own pipeline of antibody drugs. The Company partners with companies of all sizes, from biotechnology companies to pharmaceutical companies-propelling programs to the clinic, together. It generates a range of diverse antibodies with immunization strategies and single-cell screening.

Number of employees: 586

Sales per Business

USD in Million2022Weight2023Weight Delta
Antibodies
100.0 %
485 100.0 % 38 100.0 % -92.17%

Sales per region

USD in Million2022Weight2023Weight Delta
Canada
94.7 %
484 99.8 % 36 94.7 % -92.57%
United States
5.3 %
1 0.2 % 2 5.3 % +66.67%

Managers

Managers TitleAgeSince
Founder 39 07/11/12
Founder - 07/11/12
Chief Executive Officer 49 07/11/12
Director of Finance/CFO 51 31/05/16
Compliance Officer 54 31/07/19
Chief Tech/Sci/R&D Officer - -
Investor Relations Contact - -
Corporate Officer/Principal - -
Corporate Officer/Principal 54 01/12/21
Comptroller/Controller/Auditor - -

Members of the board

Members of the board TitleAgeSince
Director/Board Member 59 31/10/20
Director/Board Member 72 30/09/19
Director/Board Member 63 06/12/21
Director of Finance/CFO 51 31/05/16
Chief Executive Officer 49 07/11/12
Founder 39 07/11/12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 292,782,152 210,498,768 ( 71.90 %) 0 71.90 %

Shareholders

NameEquities%Valuation
56,532,118 19.31 % 256 M $
Baillie Gifford & Co.
8.213 %
24,044,796 8.213 % 109 M $
Baker Bros. Advisors LP
7.825 %
22,909,753 7.825 % 104 M $
Voya Investment Management Co. LLC
3.629 %
10,624,185 3.629 % 48 M $
Thiel Capital LLC
3.477 %
10,179,880 3.477 % 46 M $
9,530,340 3.255 % 43 M $
Capital Research & Management Co. (World Investors)
2.852 %
8,351,293 2.852 % 38 M $
MultiConcept Fund Management SA
1.564 %
4,578,250 1.564 % 21 M $
OrbiMed Advisors Private Equity
1.428 %
4,180,768 1.428 % 19 M $
The Founders Fund Management LLC
1.428 %
4,180,547 1.428 % 19 M $

Company contact information

AbCellera Biologics, Inc.

2215 Yukon Street

V5Y 0A1, Vancouver

+604-559-9005

http://www.abcellera.com
address AbCellera Biologics Inc.(ABCL)
  1. Stock Market
  2. Equities
  3. ABCL Stock
  4. Company AbCellera Biologics Inc.